We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer’s and BioNTech’s experimental COVID-19 vaccine BNT162b2 has been chosen for a phase 2/3 efficacy study of 9,000 participants following its success in a phase 1 trial. Read More
Sinopharm has announced that it will launch another phase 3 trial of its experimental COVID-19 vaccine candidate, this time in Peru, following a greenlight from the Peruvian health regulator. Read More
Johnson & Johnson (J&J) expects to begin the largest late-stage trial for a COVID-19 vaccine candidate to date early next month if results from its early-stage studies pan out. Read More
The data also “showed that similar percentages of patients improved between the two treatment arms, 57 percent for tradipitant and 50 percent for placebo,” Vanda acknowledged. Read More
Hospitalized COVID-19 patients with pneumonia improved sooner when treated with Vanda Pharmaceuticals’ investigational anti-inflammatory drug tradipitant compared to a placebo, according to interim results from a phase 3 trial. Read More
A second study evaluating the use of the popular heartburn drug famotidine in patients with severe COVID-19 has found that the treatment reduced deaths and the need for intubation. Read More